- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: HMPL-309 | HMPL309 | theliatinib
Compound class: Synthetic organic
Comment: Xiliertinib (HMPL-309) is an ATP-competitive EGFR tyrosine kinase inhibitor that was developed for anticancer potential .
Theliatinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but was not submitted to the World Health Organisation for ratification.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|International Nonproprietary Names
|HMPL-309 | HMPL309 | theliatinib
|CAS Registry No.
|1353644-70-8 (source: WHO INN record)
|GtoPdb PubChem SID
|Search Google for chemical match using the InChIKey
|Search Google for chemicals with the same backbone
|Search PubMed clinical trials
|Search PubMed titles
|Search PubMed titles/abstracts
|UniChem Compound Search for chemical match using the InChIKey
|UniChem Connectivity Search for chemical match using the InChIKey